AbbVie’s Humira drug faces competition in the U.S., FT reports

AbbVie (ABBV) has aggressively protected its exclusive rights to sell Humira in the U.S. for the past two decades, which has allowed the company to increase drug prices, Jamie Smyth of The Financial Times reports. Now, AbbVie will be facing competition for the first time in U.S. when Amgen (AMGN) launches a copycat version of the drug. Amgen’s version could halve the cost for insurers, employers, the government, and patients alike. Reference Link